Otsuka Pharmaceutical Development & Commercialization, Inc.
Princeton, New Jersey, United States
Purpose
to clinically evaluate a novel three drug regimen (delamanid, OPC-167832, bedaquiline) TB drug regimen for a pan-TB indication
Division
Global Health
Date
June 2021
Region Served
GLOBAL
Committed amount
$14,763,693
Grant topic
Tuberculosis
Duration (months)
54
Grantee location
Princeton, New Jersey, United States
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.